# Vaccines for Children

Canonical: https://abierto.us/opportunities/75d30125r00065

- Solicitation number: 75D30125R00065
- Notice type: Justification (first published as combined synopsis and solicitation)
- Status: Awarded to Merck Sharp & Dohme LLC
- Department: Department of Health and Human Services
- Agency: Centers for Disease Control and Prevention
- Contracting office: CDC Office of Acquisition Services (75D301)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: Atlanta, Georgia
- County: DeKalb County (FIPS 13089). https://abierto.us/counties/dekalb-county-ga-13089
- City: Atlanta. https://abierto.us/cities/atlanta-ga-1304000
- First posted: January 16, 2025
- Last posted: August 21, 2025
- SAM.gov: https://sam.gov/workspace/contract/opp/f2d9e485bef946efb0c581678f9998f0/view

## Description

CDC Office of Acquisition Services awarded multiple indefinite delivery, indefinite quantity (IDIQ) contracts for the National Center for Immunization and Respiratory Diseases (NCIRD) for the purchase of standard commercial pediatric & adult vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA).

The vaccines awarded under these contracts will be purchased for NCIRD’s immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and VFC, as established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993. The initial pediatric contracts, awarded in April 2025 were established to support public sector ACIP recommended routine vaccinations for children.

Merck’s pediatric contract will be modified to support purchase of Clesrovimab (Enflonsia), which is indicated for the prevention of RSV lower respiratory tract disease, hospitalization, and death in neonates and infants who are born during or entering their first RSV season, in light of the ACIP approval and accompanying VFC resolution on June 25, 2025. Clesrovimab from Merck is the second product currently licensed for the prevention of RSV in neonates and infants to prevent severe RSV disease.

CDC’s current pediatric contract with Merck will be modified to include ~750,000 doses required to support purchase of Clesrovimab to administer to VFC eligible neonates and newborns. CDC intends on awarding a sole source follow on action to Merck to allow for the addition of Clesrovimab. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.

## Award on USAspending

- Recipient: Pfizer Inc. (UEI MHBQULRMEEJ5)
- Contract: 75D30125D00194
- Obligated: $1,123,734,611.80
- Competition: Full and Open Competition, 5 offers received
- Link: solicitation number 75D30125R00065 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_IDV_75D30125D00194_7523/

- Recipient: Merck Sharp & Dohme LLC (UEI FCFDA78HKKG2)
- Contract: 75D30125D00195
- Obligated: $2,407,704,840.05
- Competition: Full and Open Competition, 5 offers received
- Link: award number 75D30125D00195 equals the contract number; same awarding office 75D301 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_IDV_75D30125D00195_7523/

- Recipient: Sanofi Vaccines US Inc. (UEI NCXBGGQ8YTU9)
- Contract: 75D30125D00196
- Obligated: $964,721,458.19
- Competition: Full and Open Competition, 5 offers received
- Link: solicitation number 75D30125R00065 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_IDV_75D30125D00196_7523/

- Recipient: Bavarian Nordic, Inc. (UEI LA6TFGKSSFC1)
- Contract: 75D30125D00197
- Obligated: $527,850.00
- Competition: Full and Open Competition, 5 offers received
- Link: solicitation number 75D30125R00065 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_IDV_75D30125D00197_7523/

- Recipient: Glaxosmithkline, LLC (UEI FRHTPHMZMX47)
- Contract: 75D30125D00198
- Obligated: $793,016,569.64
- Competition: Full and Open Competition, 5 offers received
- Link: solicitation number 75D30125R00065 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_IDV_75D30125D00198_7523/


## Publications

- January 16, 2025: Combined synopsis and solicitation, due January 30, 2025 at 1:00 PM EST. Notice f79fa6f1ec60479f881a05c40d8dd555. https://sam.gov/workspace/contract/opp/f79fa6f1ec60479f881a05c40d8dd555/view
- January 17, 2025: Combined synopsis and solicitation, due January 30, 2025 at 1:00 PM EST. Notice 9ec6c03e10c848ea8718a6c6838d9e33. https://sam.gov/workspace/contract/opp/9ec6c03e10c848ea8718a6c6838d9e33/view
- January 17, 2025: Combined synopsis and solicitation, due January 30, 2025 at 1:00 PM EST. Notice cc30712f220748248369bc7368efe7a4. https://sam.gov/workspace/contract/opp/cc30712f220748248369bc7368efe7a4/view
- August 21, 2025: Justification. Notice f2d9e485bef946efb0c581678f9998f0. https://sam.gov/workspace/contract/opp/f2d9e485bef946efb0c581678f9998f0/view

## Points of contact

- James Sprigler, zbs6@cdc.gov
- Chad Turner, ukr9@cdc.gov

---
Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75d30125r00065.